Sandoz on Tuesday announced the launch of a generic version of AstraZeneca’s Pulmicort Respules (budesonide inhalation suspension) in 1-mg strength. Sandoz expects to have 180-day generic drug marketing exclusivity for the 1-mg strength.
As the sole U.S. supplier of fluoxymesterone, Upsher-Smith sought a way to renew the product’s availability after the company’s initial API manufacturer discontinued its supply.
The Israeli Health Ministry approved on Monday a decision to allow patients licensed to receive medical marijuana from a pharmacy with authorization from a medical expert, according to theJerusalem Post.
The Food and Drug administration announced Friday that it had approved Praluent (alirocumab), a cholesterol-lowering PCSK9 inhibitor injection.
The FDA has approved Daklinza (daclatasvir), in combination with sofosbuvir, in treatment for chronic hepatitis C virus genotype 3 infections.
In a move that will reshape the generic pharmaceuticals landscape, Teva announced Monday that it would be acquiring Allergan Generics for $40.5 billion.
Anthem, Inc. will acquire all outstanding shares of Cigna Corporation in a transaction valued at $54.2 billion.
The National Association of Chain Drug Stores today announced that the Exhibit Hall for the 2015 NACDS Total Store Expo, which will take place from Aug. 22 to 25 at the Colorado Convention Center in Denver, is sold out.
The Food and Drug Administration announced Friday that it had approved Novartis’ Odomzo (sonidegib). The drug is meant to treat basal cell carcinoma, the most common form of advanced skin cancer.
The Food and Drug Administration announced Friday that it approved Technivie (ombitasvir, paritaprevir and ritonavir) for use in combination with ribavirin for the treatment of hepatitis C virus (HCV) genotype 4 infections in patients without scarring and cirrhosis.